Effect of Propofol on Cardioprotective Role of Remote Ischemic Preconditioning (RIPC)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02932722

Enrollment

Registered

2016-10-13

Start date

2017-02-22

Completion date

2018-02-07

Last updated

2018-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

Propofol, Sevoflurane, Preconditioning

Brief summary

This study involves research using human subjects (cardiac surgical patients) to evaluate the effect of remote ischemic preconditioning (RIPC) on cardioprotective outcomes. RIPC applied to upper or lower extremities has been shown cardioprotective role by lowering release of cardiac troponin in patients with cardiac diseases. However, it is not clear whether anesthetics, such as propofol or sevoflurane, may impair the cardioprotective effect of RIPC in cardiac surgical patients. Therefore, the purpose of the study is to compare the effects of anesthetics on cardioprotection of RIPC in patients undergoing cardiac surgery.

Detailed description

Patients undergoing cardiac surgery using cardiopulmonary bypass will be randomized to control, propofol, or sevoflurane group. Patients in the control group will receive remote ischemic preconditioning (RIPC) on their upper arms before anesthetic induction. Patients in the propofol or sevoflurane groups will receive RIPC after anesthetic induction using propofol or sevoflurane, respectively. In all patients, arterial blood samples will be obtained before and after each RIPC. From the samples, human dialysate will be obtained and perfused to rat heart through Langendorff apparatus before ischemia-reperfusion injury to the rat heart. Infarct size of the sectioned rat heart will be compared among the three - control, propofol, and sevoflurane - groups.

Interventions

OTHERControl

Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.

DRUGPropofol

Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.

DRUGSevoflurane

Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* ASA class I\ III patients undergoing cardiac surgery using cardiopulmonary bypass

Exclusion criteria

* Cardiac surgery without using cardiopulmonary bypass * Descending thoracic aortic surgery * Strenuous exercise, excessive alcohol or caffeine intake 24 hours before remote ischemic preconditioning * Left ventricular ejection fraction \< 30% * Uncontrolled hypertension or diabetes mellitus * Severe renal or hepatic dysfunction * Patients on hemodialysis * Patients with arterio-venous fistula on arms or any reason to protect arms * Peripheral vascular or nerve disease, bleeding tendency * Preoperative use of IABP, ECMO, or ventricular assist devices * Emergency operation, redo operation * Refuse to enroll * Pregnancy * Preoperative use of beta-blockers

Design outcomes

Primary

Measure	Time frame
Infarct size of the rat heart	1 day after ischemia-reperfusion injury

Secondary

Measure	Time frame
Cardiac troponin I after surgery	72 hours postoperatively
Major adverse cardiovascular and cerebrovascular events	Through study completion, average of 2 weeks before hospital discharge

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026